All eyes on new modality launches, cancer and rare disease data in 3Q19
Investors to watch new modality launches and cancer and rare disease data in a light 3Q19
While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs.
Of special interest to multiple buysiders is the launch of SMA gene therapy Zolgensma onasemnogene abeparvovec-xioi from the AveXis Inc. unit of Novartis AG, which could be the first litmus test of gene therapy's commercial potential.
“It’s important that the first few launches support the idea that these can be big commercial products and that the valuations of these companies are warranted,” Loncar Fund’s Brad Loncar said.
On the clinical data front, rare diseases and cancer will continue to command investor attention.
Buysiders will also be awaiting commercial and regulatory updates that could catalyze M&A.
New modalities on the market
So far most of the new modality products on the market have done reasonably well versus expectations, with the caveat that, other than Biogen Inc.'s Spinraza nusinersen, they’re still in the early phases of their launches.
However, OrbiMed's Sven Borho said the significance of other new modality launches pales in comparison to that of Zolgensma. “AveXis is important, but I think that’s the only one.”
Loncar noted that Zolgensma stands out as a particularly good case study for gene therapy because it is entering an Orphan market where a disease-modifying therapy -- Spinraza -- is already heavily used.
“It will give us a good window into how gene therapies compete in a market for which they’re not the only show in town,” said Loncar.
“It will give us a good window into how gene therapies compete in a market for which they’re not the only show in town.”
FDA approved Zolgensma on May 24, with Novartis announcing a price of $2.125 million. The Swiss pharma was hoping to employ an outcomes-based contract that put the majority of Zolgensma’s price at risk, similar to bluebird bio Inc.’s European commercial plans for its β thalassemia gene therapy Zynteglo. Those plans appear to have been scuppered by Medicaid’s best price rule, at least for now (see “Zolgensma’s Label More Surprising than its Price” and “Unsung Public Policy Innovators”).
Sales data from